

Dabrafenib BREAK-3

### PRELIMINARY SCORE

#### CURATIVE



#### NON-CURATIVE



### ADJUSTMENTS

#### Quality of life



#### Serious and disabling adverse effects



#### Other adjustments



Dabrafenib BREAK-3

### SCORE

#### CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

#### NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

#### INFORMATION

Tumour type: Skin Cancers  
Therapeutic Indication: Treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation  
Experimental Arm: Dabrafenib  
Control Arm: Dacarbazine

